Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease that involves synovial tissue and leads to joint destruction. There are currently 5 tumor necrosis factor (TNF) antagonists licensed for the treatment of RA. This review summarizes the predictors of response to TNF antagonists in RA. Demographic variables were found to predict response, although not consistently. The variables associated with poor clinical response were presence of radiographic joint erosions at baseline, poor functional capacity at baseline, presence of human antibodies against TNF chimeric antibodies, and increase in anti-DNA and antinuclear antibodies. In selected populations, polymorphisms of TNF, TNF receptor, and Fc γ receptor were related to clinical response. Expression of TNF and other inflammatory cytokines in synovial tissue was explored. The heterogeneity of study populations limits the generalizability of the results in most studies.
Keywords: Rheumatoid arthritis, response, biomarkers, TNF antagonists.
Current Pharmaceutical Design
Title:Predictors of Response to TNF Antagonists
Volume: 21 Issue: 2
Author(s): Eva Salgado, Jose Ramon Maneiro and Juan J. Gomez-Reino
Affiliation:
Keywords: Rheumatoid arthritis, response, biomarkers, TNF antagonists.
Abstract: Rheumatoid arthritis (RA) is a chronic inflammatory disease that involves synovial tissue and leads to joint destruction. There are currently 5 tumor necrosis factor (TNF) antagonists licensed for the treatment of RA. This review summarizes the predictors of response to TNF antagonists in RA. Demographic variables were found to predict response, although not consistently. The variables associated with poor clinical response were presence of radiographic joint erosions at baseline, poor functional capacity at baseline, presence of human antibodies against TNF chimeric antibodies, and increase in anti-DNA and antinuclear antibodies. In selected populations, polymorphisms of TNF, TNF receptor, and Fc γ receptor were related to clinical response. Expression of TNF and other inflammatory cytokines in synovial tissue was explored. The heterogeneity of study populations limits the generalizability of the results in most studies.
Export Options
About this article
Cite this article as:
Salgado Eva, Ramon Maneiro Jose and Gomez-Reino Juan J., Predictors of Response to TNF Antagonists, Current Pharmaceutical Design 2015; 21 (2) . https://dx.doi.org/10.2174/1381612820666140825124152
DOI https://dx.doi.org/10.2174/1381612820666140825124152 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Perspectives in Celiac Disease Therapy
Mini-Reviews in Medicinal Chemistry Silencing of Tumor Necrosis Factor Receptor-1 in Human Lung Microvascular Endothelial Cells Using Particle Platforms for siRNA Delivery
Current Drug Targets Novel Approaches to the Therapy of Rheumatoid Arthritis based on an Understanding of Disease Mechanisms
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Leukocyte Adhesion: A Suitable Target for Anti-Inflammatory Drugs
Current Pharmaceutical Design HLA and Non-HLA Genes in Ankylosing Spondylitis and Seronegative Spondyloarthritis in Asia
Current Rheumatology Reviews Patent Annotations
Recent Patents on Cardiovascular Drug Discovery The Anti-Inflammatory and Pharmacological Actions of Oleocanthal, a Phenolic Contained in Extra Virgin Olive Oil
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design Antagonism by Bioactive Polyphenols Against Inflammation: A Systematic View
Inflammation & Allergy - Drug Targets (Discontinued) An Overview of Olive Oil Biomolecules
Current Biotechnology Cardio-Rheumatology: Two Collaborating Disciplines to Deal with the Enhanced Cardiovascular Risk in Autoimmune Rheumatic Diseases
Current Vascular Pharmacology Therapeutic Agents Against COVID-19 with Clinical Evidence
Current Pharmaceutical Design Molecules of Parasites as Immunomodulatory Drugs
Current Topics in Medicinal Chemistry The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine The Cross-talk between Tristetraprolin and Cytokines in Cancer
Anti-Cancer Agents in Medicinal Chemistry Extensive Coronary Calcification: A Clinically Unrecognised Condition
Current Vascular Pharmacology Monoclonal Antibody Therapy in Haematological Malignancies
Current Clinical Pharmacology RNA-Mediated Therapeutics: From Gene Inactivation to Clinical Application
Current Topics in Medicinal Chemistry The Contribution of γδ T Cells to the Pathogenesis of EAE and MS
Current Molecular Medicine Interaction of Cyclosporine A and the Renin-Angiotensin System New Perspectives
Current Drug Metabolism